Streetbeat News

Regulatory

SPY

USO

VGK

Russian President Vladimir Putin has dismissed reports of a possible nuclear weapon in Ukraine as a provocation, stating that Russia will not allow Ukraine to obtain nuclear weapons. He emphasized the difficulty of concealing nuclear weapons in Ukraine.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 2:14 pm

AAPL

DOGE

NFLX

TSM

The article covers a range of topics including a 20% surge in iPhone 16 sales in China, Netflix's Q3 earnings boosting US market optimism, and a potential crypto surge as US elections and a Fed rate cut approach. It also mentions TSMC's impact on the Dow, Dogecoin's rally, and various political and economic developments.

Portfolio Pulse from Akanksha Bakshi

October 18, 2024 | 2:02 pm

The FAA announced a new safety review of Boeing's processes, expected to take about three months. This review is part of the FAA's oversight to ensure Boeing's safety culture improvements are sustained.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 1:29 pm

TSLA

Tesla faces potential delays in launching its Full Self-Driving (FSD) feature in China due to regulatory hurdles. Despite plans to launch by Q1 2025, approval is pending, and data security issues are a concern. Tesla offers a limited-time FSD transfer opportunity for Chinese customers.

Portfolio Pulse from Nabaparna Bhattacharya

October 18, 2024 | 1:26 pm

PNW

The U.S. Department of Energy has awarded $70 million to Arizona Public Service (APS) for smart grid resilience and wildfire mitigation. This includes $50 million for wildfire prevention and $20 million for enhancing smart grid technology in rural and tribal communities.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 1:04 pm

TBPH

Theravance has published a sub-study of its 12-week, randomized, registrational Phase 3 trials for YUPELRI, focusing on the drug Revefenacin. This development is significant for the company as it progresses in its clinical trials.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 1:04 pm

ENPH

FSLR

NEE

NOVA

RUN

Analysts are closely watching renewable energy companies like First Solar, NextEra, and Enphase as potential market movers post-election. Depending on the election outcome, these companies could experience a relief rally or face uncertainty. A Democrat sweep or Trump/Harris win with a split Congress could benefit renewables, while a Trump victory with a split Congress could particularly favor First Solar due to potential tariffs. Sunrun and Sunnova could also benefit from a split Congress, but a Republican sweep might delay investor enthusiasm.

Portfolio Pulse from Surbhi Jain

October 18, 2024 | 12:46 pm

GILD

Gilead Sciences has decided to withdraw the U.S. accelerated approval for its drug Trodelvy in treating metastatic urothelial cancer after the TROPiCS-04 study failed to meet the overall survival endpoint. Other indications for Trodelvy remain unaffected.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:37 pm

ICU

SeaStar Medical has reached a significant milestone in its adult acute kidney injury trial by enrolling 51 subjects, surpassing the halfway mark. The accelerated recruitment is bringing the trial closer to its 100-subject interim analysis target, which will evaluate the 90-day primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:32 pm

ARQT

Arcutis Biotherapeutics has received Health Canada approval for ZORYVE Foam 0.3% to treat seborrheic dermatitis in patients aged 9 and older. This marks the first new mechanism topical treatment for the condition in Canada in over 20 years.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:22 pm